FDA New Drug and Biologic Approvals -- 2017 Year-in-Review

Mary L Windle, PharmD


January 11, 2018

In This Article

Besponsa (inotuzumab ozogamicin)


Relapsed or refractory B-cell precursor acute lymphoblastic leukemia.


CD22-directed antibody-drug conjugate (ADC) recognizes human CD22; small molecule N-acetyl-gamma-calicheamicin is a cytotoxic agent that covalently attaches to antibody via a linker.


Total dose of inotuzumab is 1.8 mg/m² per 21-day cycle, administered as 3 divided doses on day 1 (0.8 mg/m²) and on days 8 and 15 (0.5 mg/m²). Dose for subsequent cycles is dependent on response following cycle 1.


Approval was based on findings from the phase 3 INO-VATE trial, which compared inotuzumab with one of 3 standard chemotherapy regimens. The risk of progression or death was reduced by 55% with inotuzumab vs. standard therapy. Overall, a complete response (CR) or CR with incomplete hematologic recovery (CR/CRi) was experienced by 80.7% in the inotuzumab arm compared with 29.4% with chemotherapy.


Kantarjian HM, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016. 375:740-53.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.